Ob/Gyn Medical News about postmenopausal osteoporosis; once-monthly oral ibandronate

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Once-monthly oral ibandronate in postmenopausal osteoporosis: Translation and updated review
Clinical Therapeutics, 08/19/09

Rossini M et al. – Based on the findings from the studies included in the present review, treatment with oral ibandronate 150 mg once monthly was reported to be at least as effective as the daily regimen and was associated with increased adherence. Monthly iban–dronate might provide an option for the treatment of postmenopausal osteoporosis.

Methods

A search of MEDLINE (key terms: ibandronate and ibandronic acid; publication dates: 1996–December 2008) was used to identify studies of the efficacy and adherence of ibandronate in the treatment of postmenopausal osteoporosis.

Results

A total of 15 articles were included in the present review.
An analysis of data from 2 US data–bases reported that once–monthly ibandronate was associated with significantly improved treatment persistence relative to weekly bisphosphonates at 1 year.
In Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe, the risk for new vertebral fractures was reduced by 62% with oral ibandronate 2.5 mg/d versus placebo at 3 years.
In the 2–year Monthly Oral Ibandronate in Ladies study, oral ibandronate 150 mg once monthly was associated with significantly increased lumbar spine BMD, and bone turnover markers were numerically decreased compared with the daily regimen.
A meta–analysis reported a 38% lower risk for nonvertebral fractures with combined high doses of ibandronate (including oral iban–dronate 150 mg monthly and ibandronate 3 mg IV every 3 months) compared with oral ibandronate 2.5 mg/d

<< Previous
Breast cancer susceptibility variants alter risks in familial...

Next >>
To sweat or not to sweat? A hypothesis on the effects of...